Ruxolitinib Reverses Alopecia Areata Via a Triple Mechanism: JAK-STAT Inhibition, Localized Oxidative Stress Attenuation and Selective Apoptosis Modulation

This review examines the role of autophagy, specifically macrophage, chaperone-mediated, and microphagy, in the progression of six skin diseases, including psoriasis and systemic lupus erythematosus, illustrating its significance in cellular homeostasis.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This review compiles current evidence on the molecular mechanisms, etiologies, and targeted immunotherapies for alopecia areata and reports no new experimental results, emphasizing the need for further research to manage the disease.

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

This study found that activating Nrf2 in human hair follicles significantly reduced oxidative stress, lipid peroxidation, and protected against hair growth inhibition, suggesting a protective role for Nrf2 against redox insult in this context.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.